PNMA family member 6AGenealiases: MA6 · PNMA6 · PNMA6C
Q-omics provides the consensus-scored PNMA6A profile across patient tissues and cancer cell-line models. PNMA6A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, PNMA6A is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, PNMA6A RNA expression shows 17,447 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SCLC, KICH, and GBM as cancer lineages where PNMA6A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNMA6A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNMA6A survival associations across molecular data types. PNMA6A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNMA6A RNA expression–survival associations across cancer types. High PNMA6A expression shows unfavorable associations in SCLC, ACC, SKCM and UCS, but favorable associations in KIRC and KIRP. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for PNMA6A RNA expression.
This table summarizes PNMA6A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PNMA6A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNMA6A shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in LUAD, KIRC and HNSC. The KICH box plot shows higher PNMA6A RNA expression in normal versus tumor tissue (log2 FC = −1.126, t-test p < 0.001).
This table shows molecular features associated with PNMA6A in patient tissues and cancer cell lines. In patient samples, PNMA6A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PNMA6A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
